23 completed, 16 recruiting, 14 unknown, 7 terminated. 44 Phase 2, 17 Phase 1, 9 Not applicable, 4 Phase 3, 3 Phase 4.
Follow Severe Aplastic Anemia: new trials by email Literature Review of Severe Aplastic Anemia trials Research Report on Severe Aplastic Anemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Thiotepa-Based Conditioning for Haploidentical Hematopoietic Stem Cell Transplantation in Older Patients With Severe Aplastic Anemia Thiotepa - Severe Aplastic Anemia, Hematopoietic Cell Transplant | Not yet recruiting | Peking University People's Hospital | 20 | 2026-09-20 | 2026-09-21 | |
| A Novel Conditioning Regimen for Haplo-HSCT in Older Patients With SAA BFCA conditiong regimen - Severe Aplastic Anemia, Aplastic Anaemia | Recruiting | Peking University People's Hospital | 64 | 2026-06-01 | 2026-07-06 | |
| Safety and Efficacy of the JAK1 Inhibitor Combined With Intensive Immunosuppressive Therapy in Severe Aplastic Anemia Golidocitinib Capsules - Severe Aplastic Anemia, Refractory Aplastic Anemia | Phase 1 / Phase 2 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 42 | 2025-12-15 | 2025-12-22 |
| CD7 CAR T Cells (RD13-02) in the Treatment of Relapsed/Refractory Severe Aplastic Anemia RD13-02 - Severe Aplastic Anemia, Relapse | Phase 1 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 15 | 2025-06-19 | 2025-07-24 |
| Clinical Trial of Upfront Haploidentical or Unrelated Donor BMT to Restore Normal Hematopoiesis in Aplastic Anemia Haploidentical donor bone marrow transplant, Unrelated donor bone marrow transplant - Severe Aplastic Anemia | Phase 2 | Recruiting | Medical College of Wisconsin | 60 | 2025-05-12 | 2026-02-17 |
| Reduced Dose of Cyclophosphamide Combined With Standard Immunosuppressive Therapy to Treat Severe Aplastic Anemia Reduced dose of cyclophosphamide combined with standard immunosuppressive therapy - Severe Aplastic Anemia, Cyclophosphamide Reduced-dose | Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 75 | 2024-11-01 | 2024-11-19 |
| MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure. Rituximab, Rabbit ATG, Cyclophosphamide - Severe Aplastic Anemia, Acquired Amegakaryocytic Thrombocytopenia | Phase 2 | Recruiting | Masonic Cancer Center, University of Minnesota | 60 | 2024-06-05 | 2026-06-03 |
| Clinical Study on Modified Allogeneic Hematopoietic Stem Cell Transplantation Regimen for Severe Aplastic Anemia Modified transplantation system - Severe Aplastic Anemia | Phase 2 | Recruiting | Hematology department of the 920th hospital | 30 | 2024-03-01 | 2024-04-22 |
| Sirolimus+Abatacept+Mycophenolate Mofetil for Prophylaxis of aGVHD in Patients Receiving Haplo-HSCT Who Are Intolerant to Calcineurin Inhibitors Sirolimus, Abatacept, MMF - Acute Leukemia, Myelodysplastic Syndromes | Phase 1 / Phase 2 | Unknown | Peking University People's Hospital | 6 | 2024-03-01 | 2024-03-21 |
| JAK1/2 Inhibitor Ruxolitinib for Relapsed/Refractory Immune Bone Marrow Failure Ruxolitinib - Severe Aplastic Anemia, Single Lineage Cytopenias, T-LGL | Phase 1 / Phase 2 | Active not recruiting | National Heart, Lung, and Blood Institute (NHLBI) | 13 | 2024-02-20 | 2026-10-14 |
| Haploidentical Hematopoietic Cell Transplantation Using TCR Alpha/Beta and CD19 Depletion CliniMACS - Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia in Remission | Not applicable | Active not recruiting | Baylor College of Medicine | 3 | 2023-12-06 | 2026-10-08 |
| The Optimization of Conditioning Regimen for HLA Matched HSCT in SAA Busulfan, Flu/Cy/ATG or Cy/ATG - Severe Aplastic Anemia | Phase 4 | Unknown | Peking University People's Hospital | 160 | 2023-11-15 | 2023-11-18 |
| Conditioning Regimen Containing Low Dose ATG for The Treatment of Acquired SAA Receiving sUCBT Anti-Thymocyte Globulin (Rabbit) - Severe Aplastic Anemia | Unknown | Anhui Provincial Hospital | 72 | 2023-10-01 | 2023-10-24 | |
| Cyclophosphamide Added to Standard Immunosuppressive Therapy With Herombopag as Front-line Therapy in Patients With Severe Aplastic Anemia Cyclophosphamide added to standard immunosuppressive therapy with herombopag - Severe Aplastic Anemia | Phase 2 | Unknown | Institute of Hematology & Blood Diseases Hospital, China | 43 | 2023-07-10 | 2024-09-25 |
| Rituximab for Serious Aplastic Anemia With Platelet Transfusion Refractoriness Rituximab - Severe Aplastic Anemia, Platelet Transfusion Refractoriness | Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 20 | 2023-02-23 | 2024-02-12 |
| A Trial Comparing Unrelated Donor BMT With IST for Pediatric and Young Adult Patients With Severe Aplastic Anemia (TransIT, BMT CTN 2202) cyclosporine, Matched Unrelated Donor Hematopoetic Stem Cell Transplant, horse anti-thymocyte globulin (ATG) - Severe Aplastic Anemia | Phase 3 | Terminated | Boston Children's Hospital | 53 | 2023-01-25 | 2026-10-19 |
| Avatrombopag Combined With IST as First-line Treatment for SAA avatrombopag - Severe Aplastic Anemia | Phase 2 | Unknown | Institute of Hematology & Blood Diseases Hospital, China | 53 | 2022-11-10 | 2023-02-09 |
| Phase I Clinical Study of Haplo-HSCT Combined With Hypoxic 3D-Cultured Umbilical Cord MSC for the Treatment of SAA 3D hypoxia-preconditioned UC-MSC group, 2D UC-MSC group - Severe Aplastic Anemia (SAA), Severe Aplastic Anemia, Refractory | Phase 1 / Phase 2 | Enrolling by invitation | Chinese PLA General Hospital | 40 | 2022-08-01 | 2026-06-23 |
| A Study of PEG-rhG-CSF and rhG-CSF Used for Aplastic Anemia Granulocyte Deficiency PEG-rhG-CSF - Severe Aplastic Anemia | Not applicable | Unknown | Institute of Hematology & Blood Diseases Hospital, China | 45 | 2022-06-05 | 2022-09-26 |
| Efficacy and Safety of CSA and Avatrombopag for the Treatment of SAA in the Elderly Avatrombopag - Severe Aplastic Anemia | Not applicable | Unknown | Institute of Hematology & Blood Diseases Hospital, China | 80 | 2022-06-01 | 2022-06-27 |
Showing 20 of 72. Sign in to see all of them.
Anemia, Aplastic (72) · Myelodysplastic Syndromes (12) · Lymphoma, Non-Hodgkin (9) · Bone Marrow Failure Disorders (8) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (8) · Leukemia, Myeloid, Acute (8) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (8) · Anemia, Diamond-Blackfan (6) · Anemia, Sickle Cell (6) · Hodgkin Disease (6) · Hemoglobinuria, Paroxysmal (5) · Multiple Myeloma (5) · Neutropenia, Severe Congenital, Autosomal Recessive 3 (5) · Autoimmune Diseases (4) · Fanconi Anemia (4)
Bone Marrow Diseases (72) · Hematologic Diseases (72) · Hemic and Lymphatic Diseases (72) · Anemia (71) · Bone Marrow Failure Disorders (64) · Immune System Diseases (20) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (15) · Lymphatic Diseases (14) · Immunoproliferative Disorders (13) · Genetic Diseases, Inborn (12) · Lymphoproliferative Disorders (12) · Neoplasms (12) · Neoplasms by Histologic Type (12) · Pathologic Processes (12) · Pathological Conditions, Signs and Symptoms (12)
Cyclophosphamide (15) · fludarabine (12) · Whole-Body Irradiation (10) · Antilymphocyte Serum (9) · thymoglobulin (9) · Cyclosporine (8) · Mycophenolic Acid (6) · eltrombopag (6) · Tacrolimus (5) · fludarabine phosphate (5) · Sirolimus (4) · Alemtuzumab (3) · Busulfan (3) · Rituximab (3) · Abatacept (2)
National Heart, Lung, and Blood Institute (NHLBI) (13) · Institute of Hematology & Blood Diseases Hospital, China (8) · Peking University People's Hospital (4) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (3) · Baylor College of Medicine (2) · Emory University (2) · European Society for Blood and Marrow Transplantation (2) · Jiangsu HengRui Medicine Co., Ltd. (2) · Masonic Cancer Center, University of Minnesota (2) · Medical College of Wisconsin (2) · Roswell Park Cancer Institute (2) · Anhui Provincial Hospital (1) · Assistance Publique - Hôpitaux de Paris (1) · Assiut University (1) · Boston Children's Hospital (1)
United States (42) · China (19) · France (2) · Italy (2) · South Korea (2) · Spain (2) · United Kingdom (2) · Brazil (1) · Canada (1) · Hong Kong (1) · India (1) · Mexico (1) · Netherlands (1) · Switzerland (1) · Thailand (1)
Bhavisha A Patel, M.D. (3) · Neal S Young, M.D. (3) · Danielle M Townsley, M.D. (2) · Emma M Groarke, M.D. (2) · Michael Pulsipher, MD (2) · Richard W Childs, M.D. (2) · Xiao-Jun Huang (2) · Amy DeZern, MD (1) · Amy Dezern, MD (1) · Amy E DeZern, MD (1) · Anna Pawlowska, MD (1) · Antonio M Risitano, MD, PhD (1) · Antonio Risitano, MD, PhD (1) · Bhavisha Patel, M.D. (1) · Bronwen Shaw, MD (1)
PMID 34724566, PMID 32343796, PMID 1090310, PMID 18379007, PMID 19181786, PMID 21233311, PMID 22517900, PMID 22796534, PMID 24319166, PMID 24319167, PMID 24842530, PMID 25185712, PMID 25797174, PMID 26095669, PMID 26354756, PMID 26359881, PMID 28219216, PMID 28423296, PMID 2889870, PMID 29419434, PMID 29674506, PMID 29958797, PMID 30262561, PMID 30504345, PMID 33410523, PMID 33910334, PMID 34288026, PMID 34525188, PMID 34986284, PMID 35371427, PMID 35907408, PMID 37084383, PMID 38088156, PMID 38335978, PMID 42047558
1UG3HL157564-01A1 (1), 2014 (1), 2016 (1), P01HL122173 (1), P30CA015704 (1), U10HL069294 (1), U24CA076518 (1), U24HL157560 (1)